ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO0021

Association Between Inflammation Markers in Patients with SARS-Cov-2 with the Development and Severity of AKI

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Delgado Astorga, Claudia, Hospital Civil de Guadalajara Dr Juan I Menchaca, Guadalajara, Jalisco, Mexico
  • Nava-Vargas, Miriam Gabriela, Hospital Civil de Guadalajara Dr Juan I Menchaca, Guadalajara, Jalisco, Mexico
  • Andrade-Sierra, Jorge, Universidad de Guadalajara Centro Universitario de Ciencias de la Salud, Guadalajara, Jalisco, Mexico
  • Rojas-Campos, Enrique, Hospital de Especialidades del Centro Medico Nacional de Occidente IMSS, Guadalajara, Jalisco, Mexico
Background

Acute Kidney Injure (AKI) is a common complication associated with SARS-CoV2 infection. Sepsis, direct cellular injury due to the tropism of the virus, and systemic inflammation are mechanisms involved in its development.

Methods

Prospective Cohort from March-2020 to March-2021 including 200 patients ≥18 yrs with SARS CoV2 for RT-PCR. All patients with development of AKI (KDIGO classification) during their hospitalization were registered. Age, gender, hospitalization time, oxygen use, SOFA, APACHE II, BRESCIA, PAFI,Leukocytes, creatinine (CrS) andinflammation markers (procalcitonin, ferritin, RCP, LDH, D-dimer) were registered.

Results

The incidence of AKI was 40%, 77% were male, 64% had AKI 1 and 36% were AKIN 2 y 3. The use of higher supplemental oxygen, APACHE, BRESCIA, D-Dimer and procalcitonin at day 9 and 12 were associated with AKI. In a logistic regression analysis, risk factor to AKI was septic shock (RR; 1.7-117; p=0.013). Other results are shown in Table

Conclusion

Inflammatory markers (d-Dimer and procalcitonin) were associated with the development and severity of AKI but only septic shock was predictive of the development of AKI

Comparison of socio-demographic in patients with SARS CoV-2 and AKI
 AKI=80No AKI=120p
Age (years)61 ± 1555 ± 14NS
Weight, (kg)87 ± 1986 ± 21NS
Hospitalization (days)7 ± 6.132 ± 2.0NS
Oxigen used (L/min)2.4 ± 1.17*1.8 ± 1.0*0.001
APACHE II score12.7 ± 5.78.9 ± 6.00.001
SOFA score4 ± 3.03 ± 2.3NS
Brescia-Covid score2.42 ± 1.05*1.93 ± 0.90*0.004
d-Dimer (ng/mL)2.92 ± 1.97*2.15 ± 1.6*0.007
Ferritin (ng/mL)830 ± 609791 ± 480NS
RCP (mg/dL)158 ± 112152 ± 109NS
Procalcitonin
9 Day
12 Day
2.85 ± 5.3*
3.5 ± 5.3*
0.9 ± 1.25*
0.50 ± 0.60*
0.035
0.012
CrS (AKI 1) (mg/dL)
CrS(AKI 2-3) (mg/dL)
0.81 ± 0.40*
3.0 ± 2.0*